Oil prices rose on Friday as fears of a U.S. recession eased but were on track for weekly declines of more than 4% after a jump in COVID-19 cases in top oil importer China raised the spectre of weaker fuel demand.
Brent crude futures were up 23 cents, or 0.3%, to $93.80 a barrel at 0101 GMT, extending a 1.1% rise in the previous session.
A weaker U.S. dollar boosts oil demand as it makes the commodity cheaper for buyers holding other currencies. Besides work-from-home orders reducing mobility and fuel demand, travel across China remained subdued, with people concerned about getting caught up in quarantine, ANZ Research analysts said in a note.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Oil prices dip on U.S. inventory build, China COVID worriesOil prices slipped on Wednesday after industry data showed that U.S. crude stockpiles rose more than expected and on concerns that a rebound in COVID-19 cases in top importer China would hurt fuel demand.
Les mer »
Oil falls for a fourth day as China COVID concerns growOil prices fell for a fourth day on Thursday on concerns that new COVID curbs in China, the world's biggest crude importer, will impact fuel demand.
Les mer »
Oil prices ease on U.S. inventory build, China COVID worriesOil prices slid on Wednesday as industry data showed U.S. crude stockpiles rose more than expected and on worries a rebound in COVID-19 cases in top importer China would hurt fuel demand.
Les mer »
China reports 10,729 new COVID cases for Nov 10 vs 9,005 a day earlierChina reported 10,729 new COVID-19 infections on Nov. 10, of which 1,209 were symptomatic and 9,520 were asymptomatic, the National Health Commission said on Friday.
Les mer »
China will not relax its COVID-19 measuresReuters reported that China will not relax its COVID-19 measures but will keep improving them according to the changing epidemic situation and mutatio
Les mer »
U.S.FDA panel votes against Veru's COVID-19 pillA panel of outside advisers to the U.S. health regulator on Wednesday voted against authorizing Veru Inc's drug for treating high-risk patients hospitalized with COVID-19, citing multiple concerns over efficacy and safety data being based on a small trial.
Les mer »